Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Smoking load reduction is insufficient to downregulate miR-301b, a lung cancer promoter

Full text
Author(s):
Arcas, Camila dos Santos [1] ; Lin-Wang, Hui Tzu [2] ; Kikuchi Umeda, Iracema Ioco [2, 1] ; de Sousa, Marcio Goncalves [2] ; Odagiri Utiyama, Daniela Mitiyo [3] ; Mansur, Antonio de Padua [4] ; Macchione, Mariangela [5] ; Hirata, Mario Hiroyuki [6] ; Nakagawa, Naomi Kondo [1]
Total Authors: 9
Affiliation:
[1] Univ Sao Paulo, Fac Med, Dept Physiotherapy, LIM-54, Av Dr Arnaldo, 455 Room 1150, BR-01246930 Sao Paulo, SP - Brazil
[2] Dante Pazzanese Inst Cardiol Sao Paulo State, Sao Paulo - Brazil
[3] Univ Sao Paulo, Med Rehabil Lucy Montoro Inst, Fac Med, Sao Paulo - Brazil
[4] Univ Sao Paulo, Dept Cardiopneumol, Fac Med, Sao Paulo - Brazil
[5] Univ Sao Paulo, Dept Pathol, Fac Med, LIM05, Sao Paulo - Brazil
[6] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, Sao Paulo - Brazil
Total Affiliations: 6
Document type: Journal article
Source: SCIENTIFIC REPORTS; v. 10, n. 1 DEC 3 2020.
Web of Science Citations: 1
Abstract

Several circulating miRNAs identified in the plasma of smokers have been implicated as promoters of nasopharyngeal and lung carcinoma. To investigate the plasma profile of miRNAs in subjects who reduces the number of smoked cigarettes and who quit after six months. We accompanied 28 individuals enrolled in a Smoking Cessation Program over 6 months. At Baseline, clinical characteristics, co-morbidities, and smoking history were similar among subjects. After 6 months, two groups were defined: who successfully quitted smoking (named ``quitters{''}, n=18, mean age 57 years, 11 male) and who reduced the number of cigarettes smoked (20-90%) but failed to quit smoking (named ``smokers{''}, n=10, mean age 52 years, 3 male). No significant clinical changes were observed between groups at baseline and after a 6-month period, however, quitters showed significant downregulations in seven miRNAs at baseline: miR-17 (-2.90 -fold, p=0.029), miR-20a (-3.80-fold, p=0.021); miR-20b (-4.71-fold, p=0.027); miR-30a (-3.95-fold, p=0.024); miR-93 (-3.63-fold, p=0.022); miR-125a(-1.70 -fold, p= 0.038); and miR-195 (-5.37-fold, p=0.002), and after a 6-month period in 6 miRNAs: miR-17 (-5.30-fold, p=0.012), miR-20a (-2.04-fold, p=0.017), miR-20b (-5.44-fold, p=0.017), miR-93 (-4.00-fold, p=0.041), miR-101 (-4.82-fold, p=0.047) and miR-125b (-3.65-fold, p=0.025). Using time comparisons, only quitters had significant downregulation in miR-301b (-2.29-fold, p=0.038) after 6-month. Reductions in the number of smoked cigarettes was insufficient to change the plasma profile of miRNA after 6 months. Only quitting smoking (100% reduction) significantly downregulated miR-301b related to hypoxic conditions, promotion of cell proliferation, decreases in apoptosis, cancer development, and progression as increases in radiotherapy and chemotherapy resistance. (AU)

FAPESP's process: 17/21264-7 - Predictors of inspiratory muscle weakness in patients with heart failure: clinical parameters, functional capacity and inflammatory and cardiovascular diseases biomarkers
Grantee:Naomi Kondo Nakagawa
Support Opportunities: Regular Research Grants
FAPESP's process: 13/13598-1 - Physiotherapy: functionality and biomolecular and cellular study in the treatment of patients with cardiorespiratory dysfunctions
Grantee:Naomi Kondo Nakagawa
Support Opportunities: Regular Research Grants